España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ionis Pharmaceuticals
IONS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$38.11
1.36
3.70%
At close: -
$38.37
0.26
0.68%
After Hours: 4:01 PM EDT
Get Report
Comment
Ionis Pharmaceuticals (IONS) Forecast
News
Earnings
Ionis Pharmaceuticals (IONS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Ionis Pharmaceuticals (NASDAQ:IONS) Stock
Ionis Pharmaceuticals Stock (NASDAQ: IONS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 15, 2024
Shares of pharmaceutical and healthcare stock...
Benzinga Newsdesk
Thursday, November 14, 2024
Piper Sandler Maintains Overweight on Ionis P...
Benzinga Newsdesk
Tuesday, November 12, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Thursday, November 07, 2024
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
Benzinga Insights
Wells Fargo Maintains Overweight on Ionis Pha...
Benzinga Newsdesk
Where Ionis Pharmaceuticals Stands With Analysts
Benzinga Insights
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
Wednesday, November 06, 2024
Ionis Pharmaceuticals shares are trading high...
Benzinga Newsdesk
Ionis Pharmaceuticals Q3 2024 Adj EPS $(0.72)...
Benzinga Newsdesk
Ionis Pharmaceuticals Announced The Pivotal P...
Benzinga Newsdesk
Monday, November 04, 2024
Ionis Announces FDA Acceptance Of New Drug Ap...
Benzinga Newsdesk
Thursday, October 31, 2024
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Chris Katje
Monday, October 21, 2024
Ionis And AstraZeneca's WAINZUA Recommended F...
Benzinga Newsdesk
Wednesday, October 09, 2024
Guggenheim Maintains Buy on Ionis Pharmaceuti...
Benzinga Newsdesk
Thursday, October 03, 2024
Ionis Pharmaceuticals Will Present New Three-...
Benzinga Newsdesk
Wednesday, October 02, 2024
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
Zacks
Tuesday, October 01, 2024
Ionis Pharmaceuticals' Zilganersen Gets FDA F...
Benzinga Newsdesk
Thursday, September 26, 2024
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
Benzinga Insights
RBC Capital Reiterates Outperform on Ionis Ph...
Benzinga Newsdesk
Tuesday, September 10, 2024
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Avi Kapoor
Ionis Pharmaceuticals shares are trading lowe...
Benzinga Newsdesk
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Reported Earlier, Ionis Prices $500.3M Public...
Benzinga Newsdesk
Monday, September 09, 2024
Ionis Pharmaceuticals shares are trading lowe...
Benzinga Newsdesk
Ionis Pharmaceuticals Announces $500M Public ...
Benzinga Newsdesk
Monday, August 26, 2024
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Benzinga Insights
JP Morgan Maintains Neutral on Ionis Pharmace...
Benzinga Newsdesk
Friday, August 02, 2024
Guggenheim Maintains Buy on Ionis Pharmaceuti...
Benzinga Newsdesk
Goldman Sachs Maintains Sell on Ionis Pharmac...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Ionis Phar...
Benzinga Newsdesk
12 Analysts Have This To Say About Ionis Pharmaceuticals
Benzinga Insights
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
BMO Capital Downgrades Ionis Pharmaceuticals ...
Benzinga Newsdesk
Thursday, August 01, 2024
Ionis Pharmaceuticals Q2 2024 Adj. EPS $(0.24...
Benzinga Newsdesk
Wednesday, July 31, 2024
Alcyone Therapeutics Announces Continued Enro...
Benzinga Newsdesk
Wednesday, July 24, 2024
Leerink Partners Upgrades Ionis Pharmaceutica...
Benzinga Newsdesk
Tuesday, July 23, 2024
TD Cowen Maintains Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
B of A Securities Maintains Buy on Ionis Phar...
Benzinga Newsdesk
Monday, July 22, 2024
Ionis Pharmaceuticals shares are trading high...
Benzinga Newsdesk
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Vandana Singh
Ionis Pharmaceuticals Announces Phase 1/2 Res...
Benzinga Newsdesk
Thursday, July 18, 2024
Ionis Pharmaceuticals Has Completed Enrollmen...
Benzinga Newsdesk
Tuesday, July 16, 2024
The Latest Analyst Ratings For Ionis Pharmaceuticals
Benzinga Insights
B of A Securities Maintains Buy on Ionis Phar...
Benzinga Newsdesk
Ionis Pharmaceuticals shares are trading high...
Benzinga Newsdesk
Jefferies Upgrades Ionis Pharmaceuticals to B...
Benzinga Newsdesk
Thursday, June 27, 2024
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Benzinga Insights
Stifel Maintains Hold on Ionis Pharmaceutical...
Benzinga Newsdesk
Tuesday, June 25, 2024
Ionis Pharmaceutics shares are trading higher...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch